Sight sciences chief legal officer sells shares worth $17,131

Published 07-01-2025, 08:20 am
SGHT
-

Jeremy B. Hayden, the Chief Legal Officer of Sight Sciences , Inc. (NASDAQ:SGHT), recently sold 4,864 shares of the company's common stock. The transaction comes as the stock trades near its 52-week low of $3.30, with shares down over 45% in the past six months. The shares were sold to cover tax liabilities associated with the vesting of restricted stock units. The sale, executed on January 3, 2025, was conducted at a weighted average price of $3.522 per share, amounting to a total transaction value of approximately $17,131. Following this transaction, Hayden retains direct ownership of 153,823 shares in the company. While the company maintains strong liquidity with a current ratio of 10.18, InvestingPro analysis reveals the company is quickly burning through cash. Get access to 10+ additional key insights and detailed financial analysis with an InvestingPro subscription.

In other recent news, Sight Sciences, a medical device company, has secured an additional $5 million in loan funding from its existing credit facility with Hercules Capital (NYSE:HTGC), Inc. and affiliates, raising the total borrowed amount to $40 million. The company's third-quarter revenue saw a slight increase of 1% year-over-year to $20.2 million, with surgical glaucoma revenue accounting for $18.6 million. However, surgical glaucoma revenue saw a sequential decrease of 8%, and dry eye revenue declined by 4% to $1.5 million. Sight Sciences also issued warrants to the lenders, allowing them to purchase shares of the company's common stock.

UBS has initiated coverage of Sight Sciences with a Buy rating, forecasting strong sales growth by 2026. The firm expects the company's TearCare Dry Eye solution to drive double-digit sales growth and gross margin expansion that exceeds consensus estimates for 2026 and beyond. Despite current setbacks, Sight Sciences plans to enhance sales performance and strategic positioning, remaining optimistic about growth in the surgical glaucoma and dry eye segments in 2025. These are just some of the recent developments surrounding Sight Sciences.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.